MedCity News

DECEMBER 5, 2023

Replimune’s lead therapeutic candidate did not meet the two main goals of a study intended to support an FDA submission in cutaneous squamous cell carcinoma. But Replimune’s therapy, an oncolytic virus, has better data in melanoma, and the company plans a 2024 FDA submission in this skin cancer.

Leads 107

Leads FDA Biopharma Pharma 107

PM360

FEBRUARY 23, 2024

TEAM MEMBERS: Katrina Gary Senior Director of Patient Marketing Alyson McNamara Associate Director of Patient Marketing Dan Pedersen Director Andrew Prahin Creative Director Sam Hoar Lead Copywriter Parker Gibson Lead Art Director Marisa Gurovski Account Lead OTHER BROTHER TEAM MEMBERS: Stuart Bury Executive Creative Director, Other Brother Isaiah (..)

Education 52

Education Pharma Leads Marketing 52

Clarivate

APRIL 18, 2024

In 2024, watch as the global trendsetter brings to bear its technological expertise combined with a captive Prime membership, brand recognition, and national employer buy-in to re-envision healthcare that truly works around the patient. Healthcare segment) across the nation as part of a $1 billion cost-cutting strategy.

Retail 52

Retail Healthcare Healthcare Physicians 52

Fierce Pharma

MARCH 28, 2024

[Yangzhou, China - March 26, 2024] - Aurisco Pharmaceutical, a leading global pharmaceutical company, is excited to announce the completion of its investment in cGMP peptide manufacturing capacity | Aurisco Pharmaceutical Launches State-of-the-Art Manufacturing Facility for GLP-1 Peptides

Manufacturing 138

Manufacturing Pharmaceutical Leads 138

PM360

FEBRUARY 8, 2024

THE ELEVATE HEALTHCARE MEMBERS: Scott Harper VP, Client Engagement Matt Parastino Assistant Manager, Client Engagement Tara Powers VP Creative Director, Art Sarah Ward Art Group Supervisor Carolyn Ignomirello Creative Director, Copy Tina Wack Copy Supervisor Derick Sumrall Practice Lead, Customer Experience LIVANOVA USA, INC.

Pharma 52

Pharma Sales Management Healthcare 52

PM360

FEBRUARY 8, 2024

BIOLUMINA TEAM MEMBERS: Olivia Brooman VP, Group Account Supervisor Aine McCarthy Group Account Supervisor Jason Davis SVP, Creative Director, Art John Lee Group Art Supervisor Erika Fad VP, Group Copy Supervisor Eric Niederman VP, Group Copy Supervisor Victoria Sperling Associate Editorial Director DayVaughn McKnight Editor Kelly Davila Senior Project (..)

Pharma 52

Pharma Management Leads Medical 52

pharmaphorum

JANUARY 9, 2023

is to acquire the 2015-established Amryt Pharma Plc. Supported by voting agreements from leading Amryt shareholders and directors, and unanimously approved and recommended by the boards of both companies, the total transaction is worth up to $1.48 Biopharma and healthcare group Chiesi Farmaceutici S.p.A. on 6 th January.

Pharma 90

Pharma Biopharma Management Medicine 90

Pharmaceutical Technology

MARCH 30, 2023

The US FDA has revealed its detailed budget proposal for FY2024, which would require pharma companies to name their active pharmaceutical ingredient (API) suppliers, restart President Biden’s Cancer Moonshot, inject cash into amyotrophic lateral sclerosis (ALS) research, and enforce stricter rules around manufacturing, recalls, and shortages.

Manufacturing 59

Manufacturing FDA Safety Pharma 59

MedCity News

JULY 10, 2023

A Phase 3 test of the nanoparticle-based therapy is expected to yield preliminary data in 2024. Johnson & Johnson is committing up to $60 million for global rights to a Nanobiotix therapy that enhances radiation treatment for head and neck cancer.

Leads 74

Leads Biopharma Pharma 74

European Pharmaceutical Review

SEPTEMBER 21, 2023

“A Grand Bargain is both achievable and in everyone’s interest to overcome the collective actions problems inherent in dealing with market failures in the antimicrobial market,” stated Anthony McDonnell, lead author of the report and a senior policy analyst at the CGD.

Pharma 96

Pharma Government Marketing Manufacturing 96

European Pharmaceutical Review

APRIL 15, 2024

Positive data from MaaT Pharma’s Microbiome Ecosystem Therapy TM (MET) MaaT013 as a treatment for acute graft-versus-host disease (aGvHD), is set to be presented at the 2024 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting. This data summary is based on an abstract from the Annual Meeting.

Pharma 86

Pharma Patients Management Leads 86

European Pharmaceutical Review

NOVEMBER 21, 2023

Phase III trials of a low carbon version of GSK’s metered dose inhaler, Ventolin (salbutamol), using a next generation, lower carbon propellant, are set to start in 2024. The pharma company stated that if successful, it has the potential to reduce greenhouse gas emissions from use of the inhaler by approximately 90 percent.

Manufacturing 106

Manufacturing Patients Pharma Leads 106

Clarivate

MAY 14, 2024

While initially developed to help regulate blood sugar levels, they have also been found to promote appetite suppression, leading to weight loss in patients. What’s leading to the boom in development of semaglutide biosimilars? Per recent Clarivate estimates, the therapeutic market for these drugs is valued at approximately $1.7

Manufacturing 52

Manufacturing Marketing Leads Medicine 52

Medico Reach

FEBRUARY 8, 2023

The Grand View Research published a report highlighting the stark growth prospects of the pharma industry. billion during 2020-2024. Are you intrigued to know what technologies will rule the pharma market and how they can benefit your business in 2023? from 2022 to 2030, the pharma industry will reach USD 9,241.34

Pharma 52

Pharma Medicine Marketing Prospecting 52

MedCity News

APRIL 20, 2023

A lead program with preclinical proof-of-concept data in small cell lung cancer is on track to reach the clinic in 2024. Abdera Therapeutics emerged from stealth with technology that improves the way antibodies deliver radiopharmaceuticals for cancer.

Leads 95

Leads Biopharma Pharma 95

European Pharmaceutical Review

APRIL 2, 2024

in the monographs for Water for Injection (0169) and Purified Water (0008) on 1 April 2024. on 1 January 2024. Pharma Horizons: Environmental Monitoring About the authors Evelyn Der joined Genentech, a member of the Roche Group, in 1999 and currently is in the Analytical Sciences chapter of Roche.

Ethics 87

Ethics Manufacturing Marketing Networking 87

European Pharmaceutical Review

FEBRUARY 14, 2024

Gilead confirmed that CymaBay’s lead product candidate seladelpar has a best-in-disease profile for second-line primary biliary cholangitis (PBC). ” The transaction is expected to close during the first quarter of 2024, subject to certain customary closing conditions. This is based on data from the Phase III RESPONSE trial.

Transportation 78

Transportation Patients Pharma Leads 78

European Pharmaceutical Review

DECEMBER 5, 2023

billion, enabling the Swiss pharma company to add a range of incretin treatments for obesity and diabetes to its portfolio. Carmot Therapeutics’ lead asset CT-388 is a Phase-II ready dual GLP-1/GIP agonist with best-in-class potential as a treatment for obesity in individuals with and without type 2 diabetes.

Food 91

Food Leads Pharma Patients 91

PM360

DECEMBER 12, 2023

The initial deadline for submissions is February 23, 2024. PM360 will then continue to accept entries until March 15, 2024, but anything after Feb. Established a decade ago, the PM360 ELITE honors 100 of the top individuals and marketing teams across the healthcare and life sciences industries each year.

Education 52

Education Healthcare Healthcare Marketing 52

PM360

DECEMBER 17, 2023

Publicis Groupe announced the appointment of Stephen Farquhar as Chief Executive Officer of Publicis Health, effective February 1, 2024. Farquhar previously served as Chief Marketing Officer at Publicis Media, where he led global assignments in a variety of industry verticals, including telecommunications, pharma, and CPG.

Media 52

Media Healthcare Healthcare Leads 52

World of DTC Marketing

DECEMBER 4, 2020

SUMMARY: McKinsey estimates that global digital-health revenues—from telemedicine, online pharmacies, wearable devices, and so on—will rise from $350bn last year to $600bn in 2024. The result of all this is that digital health is blazing trails, many of which will lead to a dead end. I’m not so sure. That is unacceptable.

Medicine 201

Medicine Doctors Medical Media 201

PM360

DECEMBER 20, 2023

With 2024 on the horizon, many in the biopharma space are taking stock of 2023 and what the current environment means for their potential success next year. This may best be achieved by large pharma companies, with their combined $200bn annual R&D budget, compared to smaller companies that are relying on external investment.

Biopharma 111

Biopharma Pharma Marketing Management 111

pharmaphorum

SEPTEMBER 14, 2022

That’s according to a Bloomberg report , which claims Bayer has started the search for a successor well ahead of the end of Baumann’s current contract in April 2024. Now, it seems his time at the top may be coming to an end. The post Report claims Bayer is already hunting for a new CEO appeared first on.

Pharma 90

Pharma Management Leads Marketing 90

European Pharmaceutical Review

NOVEMBER 23, 2023

For example, CPI asserted that lead times for clinical trial materials are hindering new therapies being developed. This is a first-of-its-kind collaboration for the pharma industry. CPI confirmed that the centre will establish operations during 2024 and be finished in late 2025.

Manufacturing 82

Manufacturing Medicine Government Pharmaceutical 82

PM360

FEBRUARY 8, 2024

leading technology provider for modern clinical trials, is using a new intelligent automation technology to provide faster build of standard trial timelines. In 2024, expect to see more innovative technologies and new ways of delivering streamlined, patient- centric trials from Medable.” Medable, Inc., Medable, Inc.,

Media 52

Media Electronics Patients Healthcare 52

pharmaphorum

DECEMBER 20, 2022

Verona Pharma is looking odds on for a regulatory approval for its chronic obstructive pulmonary disease (COPD) therapy ensifentrine, after chalking up a second positive phase 3 trial. COPD is the third leading cause of death worldwide, with 3.23

Pharma 57

Pharma Sales Leads Marketing 57

pharmaphorum

JANUARY 24, 2023

Pharma will be focusing more on relevant research, support, and a better mix of non-promotional and promotional interaction. Given the funding environment for innovative medicines that is faced by all pharma, large or small, once assets are approved, however, this 2023 reset seems a necessary response.

Medicine 94

Medicine Healthcare Healthcare Pharma 94

PM360

DECEMBER 20, 2023

Learn more about why each company went with its respective strategy and the current outlook for each company in 2024 and beyond. The deal is expected to close in 2024. What is your outlook for 2024 and how do you believe companies can effectively differentiate themselves? and 10X Capital Venture Acquisition Corp.

Management 109

Management Marketing Healthcare Healthcare 109

pharmaphorum

JUNE 23, 2022

The Swiss pharma group is paying $75 million upfronting cash and equity to get the ball rolling on the collaboration, with another $1.4 It is a challenging proposition, however, as delivery of the therapeutic gene sequences to cells can be difficult and raises the risk of insertion mutations that can lead to side effects, including cancer.

Side effects 84

Side effects Pharma Marketing Patients 84

PM360

APRIL 22, 2024

According to research between pharma professionals and customers, there is still room for improvement regarding prioritized customer experience. However, recent research among both pharma professionals and customers shows that there’s still a lot of work to do. Remote engagement was propelled rapidly up the list of priorities.

Pharma 52

Pharma Training Media Pharmaceutical 52

Impetus Digital

JULY 15, 2022

Here in Canada , the inflation rate is not forecasted to come back down to “normal” levels until 2024. At Impetus Digital , we understand the restrictions Pharma teams are facing right now and will not be increasing prices in the middle of the year like some vendors. Inflation or not, hybrid engagement is the future.

Healthcare Provider 95

Healthcare Provider Food Pharma Healthcare 95

pharmaphorum

JANUARY 4, 2023

MDS can lead to life threatening disease including acute myeloid leukaemia (AML), as well as anaemia and increased risk of bleeding and infections. ” Geron is also testing the drug for myelofibrosis (MF), another form of bone marrow cancer, and expects data from the phase 3 IMpactMF trial of imetelstat in relapsed/refractory MF in 2024.

Safety 98

Safety Marketing Patients Pharma 98

European Pharmaceutical Review

JUNE 27, 2023

For World Microbiome Day on 27 June 2023, EPR put questions to Hervé Affagard, CEO and co-founder of MaaT Pharma and Jeffrey Silber, Chief Medical Officer of Vedanta Biosciences, to find out how the field is progressing and what innovations could transform future microbiome-based therapies.

Food and Drug Administration 97

Food and Drug Administration Manufacturing Medicine Pharma 97

pharmaphorum

SEPTEMBER 8, 2022

The drug is already in a pair of phase 3 trials in HNSCC, with results due from 2024 onwards. “There is a clear need for improved treatment options for patients with unresected locally advanced head and neck cancer,” commented Prof Jean Bourhis of the University Hospital of Lausanne, the lead investigator of the study.

Recruitment 52

Recruitment Pharma Patients FDA 52

Eversana Intouch

MARCH 19, 2024

That’s why in 2024, we find ourselves still failing women in healthcare. Brands like Bodyform, Modybodi and many other pharma brands are leading women’s healthcare marketing to highlight the raw, authentic emotions that come with being a woman, but are rarely acknowledged. Women represent more of the health care system than men.

Healthcare 59

Healthcare Healthcare Marketing Prescription 59

Pharmaceutical Technology

JANUARY 8, 2023

Today, approximately 384 million people around the globe have COPD and it is the third leading cause of death worldwide, the Global Initiative for Chronic Obstructive Lung Disease reports. Tezspire is being studied in a Phase II COPD study (NCT04039113) that is expected to complete in March 2024. Ongoing efforts.

Patients 119

Patients FDA Pharmaceutical Pharma 119

eMediWrite

DECEMBER 22, 2023

Every year, pharma marketing teams engage in multi-phased, cross-functional, multi-organizational strategic planning and also in aligning work-stream dubbed “Brand Planning” by many in the industry. From a general perspective, despite large gains in site traffic (+16%), pharma website engagement rates were down.

Pharma 52

Pharma Marketing Distribution Leads 52